FDA-cleared profile

MR DWI/FLAIR Measurement V1.0

Olea Medical · MRI · FDA-cleared (510(k))

Authorized purpose: MR DWI/FLAIR Measurement V1.0 processes brain DWI and FLAIR MRI to calculate ADC maps, segment ADC-hypointense regions, and communicate relative or normalized FLAIR measurements; it is an adjunct and cannot be used alone for diagnosis, treatment, or patient-management decisions.

Clinical role
Automated DWI/FLAIR image processing and quantitative measurement support alongside the full native examination and other patient information.
Images and patients
MRI · Brain
Key limitation
Keep in mind: The application is not a standalone diagnostic device, does not alter the original images, and cannot be the sole basis for diagnosis, therapy, or patient management. Users must review all native images.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: MR DWI/FLAIR Measurement V1.0 processes brain DWI and FLAIR MRI to calculate ADC maps, segment ADC-hypointense regions, and communicate relative or normalized FLAIR measurements; it is an adjunct and cannot be used alone for diagnosis, treatment, or patient-management decisions.
  • Which images or clinical context are in scope?Modality: MRI Anatomy or clinical context: Brain Input: DICOM diffusion-weighted and FLAIR MR series.
  • Who uses it?Intended users: Physicians, medical technicians, and trained professionals with medical-imaging education.
  • What does the software produce?Output: ADC maps, hypointense-area segmentations, relative and normalized FLAIR images, and derived metrics for display in a DICOM viewer.
  • What is its most important limitation?Key limitation: The application is not a standalone diagnostic device, does not alter the original images, and cannot be the sole basis for diagnosis, therapy, or patient management. Users must review all native images.

Clinical takeaway. Clinical role: MR DWI/FLAIR Measurement V1.0 processes brain DWI and FLAIR MRI to calculate ADC maps, segment ADC-hypointense regions, and communicate relative or normalized FLAIR measurements; it is an adjunct and cannot be used alone for diagnosis, treatment, or patient-management decisions.

Evidence takeaway. Evidence from the reviewed source record: K230552 reports independent-institution testing of its diffusion brain-extraction model and a comparative clinical image study against Olea Sphere. Relative FLAIR bias was 0.004 with 95% limits from -0.013 to 0.021; segmentation Dice ranged from 0.816 to 0.976.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
MR DWI/FLAIR Measurement V1.0 processes brain DWI and FLAIR MRI to calculate ADC maps, segment ADC-hypointense regions, and communicate relative or normalized FLAIR measurements; it is an adjunct and cannot be used alone for diagnosis, treatment, or patient-management decisions.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Automated DWI/FLAIR image processing and quantitative measurement support alongside the full native examination and other patient information.
  • Exact FDA submission
  • Checked 2026-09-03
Required input
DICOM diffusion-weighted and FLAIR MR series.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
ADC maps, hypointense-area segmentations, relative and normalized FLAIR images, and derived metrics for display in a DICOM viewer.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Healthcare-facility MRI assessment workflows using a compatible medical image communications platform.
  • Exact FDA submission
  • Checked 2026-09-03
Intended users
Physicians, medical technicians, and trained professionals with medical-imaging education.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
The application is not a standalone diagnostic device, does not alter the original images, and cannot be the sole basis for diagnosis, therapy, or patient management. Users must review all native images.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence summary
K230552 reports independent-institution testing of its diffusion brain-extraction model and a comparative clinical image study against Olea Sphere. Relative FLAIR bias was 0.004 with 95% limits from -0.013 to 0.021; segmentation Dice ranged from 0.816 to 0.976.
  • Exact FDA submission
  • Checked 2026-09-03

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
K230552 reports independent-institution testing of its diffusion brain-extraction model and a comparative clinical image study against Olea Sphere. Relative FLAIR bias was 0.004 with 95% limits from -0.013 to 0.021; segmentation Dice ranged from 0.816 to 0.976.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03
Reported sensitivity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Sensitivity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Reported specificity
Not applicable
  • Not applicable
  • Not applicable
  • Checked 2026-09-03

Specificity is not the primary applicable endpoint for this acquisition, reconstruction, segmentation, planning, guidance, or quantitative-biomarker function. Use the task-specific endpoints and tested population reported below.

Held-out brain-extraction test cases

28 cases

  • EndpointIndependent-institution diffusion brain extraction
  • PopulationMR DWI/FLAIR Measurement V1.0
  • Tested versionMR DWI/FLAIR Measurement V1.0

Relative FLAIR average bias

0.004 ratio

  • EndpointAgreement with predicate calculation
  • PopulationMR DWI/FLAIR Measurement V1.0
  • Tested versionMR DWI/FLAIR Measurement V1.0

Relative FLAIR lower Dice

0.816 DSC

  • EndpointADC-hypointense segmentation agreement
  • PopulationMR DWI/FLAIR Measurement V1.0
  • Tested versionMR DWI/FLAIR Measurement V1.0

Relative FLAIR upper Dice

0.976 DSC

  • EndpointADC-hypointense segmentation agreement
  • PopulationMR DWI/FLAIR Measurement V1.0
  • Tested versionMR DWI/FLAIR Measurement V1.0

K230552 FDA performance package for MR DWI/FLAIR Measurement V1.0

  • DesignManufacturer held-out multi-institution brain-extraction testing and comparative clinical image agreement study
  • PopulationDWI and FLAIR brain MRI from Siemens, GE, Philips, and Canon systems
  • Scopeexact submission
  • Tested versionMR DWI/FLAIR Measurement V1.0
  • Samplen=28
  • IndependenceSponsor or vendor study

K230552

Manufacturer evidence submitted for substantial equivalence; local clinical, technical, and workflow acceptance remains necessary.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
The 2026-09-02 openFDA device-recall snapshot contained no record matched to K230552 by exact submission identifier.
  • Public source
  • Exact FDA submission
  • Checked 2026-09-03

A zero-result exact-identifier search does not prove that no recall, correction, adverse-event report, or product-family safety signal exists.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not publicly available: Reviewed sources do not publish an exact-product procurement price with a stated offer scope.

Reimbursement

Reimbursement
No separate named-product Medicare payment was identified in the reviewed CMS coverage material. Evaluate the device within the applicable imaging or surgical service line and verify payer, site-of-service, and coding assumptions independently.
  • Service-level, not product-specific
  • Checked 2026-09-03

No product-specific code

No separate named-product payment identified in reviewed public material

Centers for Medicare & Medicaid Services · United States

Build a local total-cost and value model; do not infer reimbursement from FDA clearance.

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: DICOM diffusion-weighted and FLAIR MR series.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · FDA K230552: MR DWI/FLAIR Measurement V1.0

  2. Routing

    Source context, not route validation: Containerized application with dedicated input/output channels on a compatible image-communications platform; validate DICOM series selection, vendor and protocol variation, output association, viewer display, notification, and failure handling.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-03 · FDA K230552: MR DWI/FLAIR Measurement V1.0 · Olea neurovascular imaging applications

  3. AI processing

    Source context, not route validation: A Docker application running on Olea Platform or another compatible configurable medical image communications platform.

    Scope: Exact FDA submission.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-09-03 · FDA K230552: MR DWI/FLAIR Measurement V1.0 · Olea neurovascular imaging applications

  4. Returned objects

    Source context, not route validation: ADC maps, hypointense-area segmentations, relative and normalized FLAIR images, and derived metrics for display in a DICOM viewer.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · FDA K230552: MR DWI/FLAIR Measurement V1.0

  5. Viewer/worklist/report

    Unresolved route: ADC maps, hypointense-area segmentations, relative and normalized FLAIR images, and derived metrics for display in a DICOM viewer.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · FDA K230552: MR DWI/FLAIR Measurement V1.0

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
A Docker application running on Olea Platform or another compatible configurable medical image communications platform.
  • Exact FDA submission
  • Checked 2026-09-03
Integration
Containerized application with dedicated input/output channels on a compatible image-communications platform; validate DICOM series selection, vendor and protocol variation, output association, viewer display, notification, and failure handling.
  • Exact FDA submission
  • Checked 2026-09-03
Security
K230552 describes an independently deployable container and platform-mediated file channels but does not establish a complete current security posture. Obtain the exact container provenance, hardening, identity, audit, encryption, update, backup, and incident-response package.
  • Exact FDA submission
  • Checked 2026-09-03

Confirm the controls against the exact contracted architecture and release.

Training
Only physicians, medical technicians, and trained professionals with medical-imaging education. should operate or interpret the system. Local onboarding should cover the exact release, supported population, limitations, failure examples, escalation, downtime, and competency documentation.
  • Exact FDA submission
  • Checked 2026-09-03
Monitoring
Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The application is not a standalone diagnostic device, does not alter the original images, and cannot be the sole basis for diagnosis, therapy, or patient management. Users must review all native images.
  • Exact FDA submission
  • Checked 2026-09-03

Release and scope verification

Map the installed model, build, options, population, anatomy, inputs, and outputs to K230552 before acceptance.

exact submission · checked 2026-09-03

Later product-family features are not evidence that this cleared release includes them.

Interoperability acceptance

Containerized application with dedicated input/output channels on a compatible image-communications platform; validate DICOM series selection, vendor and protocol variation, output association, viewer display, notification, and failure handling.

exact submission · checked 2026-09-03

Test representative identifiers, orientation, geometry, measurements, units, routing, failure handling, and round trips locally.

Clinical acceptance

Use a signed local test set for the supported population and workflow. Include common and difficult cases, exclusions, acquisition variation, failed or low-quality inputs, reviewer overrides, and downstream effects. The application is not a standalone diagnostic device, does not alter the original images, and cannot be the sole basis for diagnosis, therapy, or patient management. Users must review all native images.

exact submission · checked 2026-09-03

Define stop-use, escalation, rollback, and revalidation triggers before production use.

Economic evaluation

Model capital and recurring cost against net staff time after review, throughput, repeat imaging or rework, room time, consumables, infrastructure, training, service, downtime, upgrade, and replacement costs.

product family · checked 2026-09-03

Vendor productivity claims are scenario inputs, not guaranteed local savings.

Lifecycle monitoring

Monitor by exact hardware, software and model version, patient population, anatomy, protocol, operator, input quality, output edits or overrides, failed studies, repeat acquisition or rework, downstream impact, downtime, incidents, recalls, and updates. Track the limits that matter for this product: The application is not a standalone diagnostic device, does not alter the original images, and cannot be the sole basis for diagnosis, therapy, or patient management. Users must review all native images.

exact submission · checked 2026-09-03

Revalidate after material software, hardware, model, protocol, interface, or clinical-policy changes.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K230552
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
MRI
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Brain
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-04-26
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
27Fields reviewed
11Source classes checked
20Screened PubMed leads
7Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains 20 PubMed and 7 ClinicalTrials.gov candidate records. Discovery metadata alone does not establish exact tested-product, version, population, and endpoint applicability, so all candidates remain quarantined and none was promoted. The current discovery snapshot contains 20 PubMed and 7 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, vendor product page, reimbursement policy, fda device recall, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not publicly available - checked 2026-09-03 - Exact FDA submission

    No public list price for the exact cleared configuration was found. Obtain a written quote separating hardware or license basis, enabled features, implementation, interfaces, infrastructure, training, service, upgrades, renewal, consumables, and exit costs.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Installation timeline: Not yet reviewed

7 sources - 3 history items

Source ledger

  1. FDA K230552: MR DWI/FLAIR Measurement V1.0

    U.S. Food and Drug Administration - Published 2023-04-26 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, intendedUsers, input, output, limitations, evidenceSummary, clinicalUse

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  4. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  5. Medicare Coverage Database

    Centers for Medicare & Medicaid Services - Accessed 2026-09-01

    Scope: coverage, codingContext

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

  7. Olea neurovascular imaging applications

    Olea Medical - Accessed 2026-09-03

    Scope: productFamily, workflowRole, integration, implementationCapabilities, currentCommercialContext

Research history

  1. K230552 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K261405

ANDI 2.2

Imeka Solutions, Inc.

Authorized purpose: ANDI 2.2 processes brain MR images for atlas-assisted visualization, segmentation and volumetric quantification, presenting adjunctive DICOM-readable information for trained medical professionals; it does not predict, diagnose or interpret brain health.

Modality
MRI
Anatomy
Brain
Decision
2026-05-28
FDA-cleared K260032

Morph

BeauBrain Healthcare, Inc.

Authorized purpose: Morph automatically labels, visualizes, and volumetrically quantifies segmentable brain structures from MR images and may compare measurements with reference percentile data; it is adjunctive and not the sole basis for final decisions.

Modality
MRI
Anatomy
Brain
Decision
2026-05-13
FDA-cleared K253057

AI-Rad Companion Brain MR

Siemens Healthcare GmbH

Authorized purpose: Brain MRI morphometry and white matter hyperintensity quantification, including normative comparison and longitudinal change assessment for clinician review.

Modality
MRI
Anatomy
Brain
Decision
2026-01-22
FDA-cleared K252298

ANDI 2.0

Imeka Solutions, Inc.

Authorized purpose: Adjunctive quantitative brain MRI analysis that compares patient measures with normative and longitudinal references; a physician reviews all results and makes the clinical decision.

Modality
MRI
Anatomy
Brain
Decision
2025-10-22

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history